pembrolizumab
merck
['keynote-604', 'pembro', 'sclc', 'lcsm,(-blcsm)']
keynote-604: analysis phase 3 study of 1st-line (pembro) + (ep) for es-sclc. pembro+ep pfs vs placebo &amp; favored os no link between sclc subtypes &amp; os. pembro + ep benefit for tmb &lt;175 but not for tmb 175.#asco23 #lcsm 
Fellow @MayoHemeOnc | @UConnIM| @UTexasSPH| @MDAndersonNews|@COVID19nCCC| #SoMeEditor @JCOCCI_ASCO| Co-Host @HemOncFellows @LungCancerRX https://t.co/dsiuV460lQ